A Phase 1 Study of S-3304 in Patients With Solid Tumors

To determine the maximum tolerated dose and safety profile of S-3304 in patients with biopsy accessible cancer who have failed previous therapy or to whom no standard therapies are available. To determine the pharmacokinetic profile of S-3304 in this patient population

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Solid Tumors Metaplasia Neovascularization, Pathologic Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

University of Colorado Hospital, Denver, Colorado, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Biopsy proven diagnosis of solid tumor(s) with biopsy accessible lesion(s)
Must be able to tolerate oral medication Exclusion criteria
Patients with other serious illnesses
Patients who are receiving treatments

Treatment and study plan

S-3304

Drug

Sponsors and collaborators

Lead sponsor

Shionogi

Industry

Registry information

Important dates

Study start: 2001
Primary completion: 2003
Study completion: 2003
First posted: Apr 10, 2002
Registry last updated: Apr 26, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed